News from Hyrax Biosciences

Hyrax Biosciences launch Exatype Mtb!

Arrow pointing left Previous news

Dr Natasha Wood 08/05/2024

Webinar: Introducing Hyrax Bioscience’s NGS Solution for Mycobacterium Tuberculosis - Exatype Mtb

We are excited to introduce our new product, Exatype Mtb, through a 30-minute webinar that will showcase how NGS is transforming Mtb testing worldwide and demonstrate the efficient, comprehensive workflow of Exatype Mtb. If you are interested in learning more, please register for a session that best fits your time zone:

Thursday, 16 May 2024; 08h00 PDT (17h00 CEST): https://us02web.zoom.us/webinar/register/WN_50wWVIWHTXqsG7QerwQ41g#/registration

Tuesday, 21 May 2024; 10h30 CEST (14h00 IST): https://us02web.zoom.us/webinar/register/WN_ixwcjWjiRJyPvVKhMbUdzQ#/registration


During the UN High-level meeting on tuberculosis (TB) in September 20231, global leaders set ambitious goals to eradicate TB by 2030. As the second deadliest infectious disease after COVID-19, TB poses significant challenges, particularly with Mycobacterium tuberculosis (Mtb) drug-resistant forms. The complexity and high costs associated with treating drug-resistant Mtb have been longstanding issues. Traditional diagnostic methods are slow and limited, often taking months to deliver results, thereby delaying crucial treatments and complicating efforts to manage and control the disease effectively.

Next-generation sequencing (NGS) offers substantial benefits over traditional methods. With faster turnaround times, more comprehensive mutation profiling and lineage typing, NGS provides actionable drug-susceptibility and surveillance results swiftly. Moreover, the recent WHO mutation catalogue (November 2023)2 serves as a global resource linking specific mutation frequencies to their associated resistance profiles3. Used together, NGS and standardised resistance-profile interpretation establish new, efficient, and standardised methods for conducting Mtb drug-susceptibility testing and reporting.

To support the analysis of Mtb data using NGS technologies, Hyrax Biosciences recently launched Exatype Mtb for targeted and whole-genome sequencing (WGS). Incorporating the latest WHO mutation catalogue, Exatype Mtb generates comprehensive drug-susceptibility reports and lineage-typing results. True to the streamlined nature of the Exatype platform, Exatype Mtb offers a secure, cloud-based, high-throughput solution for NGS-based Mtb drug-susceptibility reporting.

With the launch of Exatype Mtb, Hyrax Biosciences not only equips global researchers and lab technicians to produce detailed and timely drug-susceptibility results but also advances scientific research aimed at achieving the UN’s goal to end TB by 2030. For further information, please visit exatype.com, hyraxbio.com, and follow us on LinkedIn.

  1. https://www.stoptb.org/news/historic-political-declaration-tb-adopted-member-states-united-nations-high-level-meeting
  2. https://www.who.int/publications/i/item/9789240082410
  3. https://www.who.int/news/item/20-03-2024-who-launches-new-guidance-on-the-use-of-targeted-next-generation-sequencing-tests-for-the-diagnosis-of-drug-resistant-tb-and-a-new-sequencing-portal